The New England Journal of Medicine has retracted a 2021 randomised controlled trial investigating avacopan for ANCA-associated vasculitis (AAV), a rare but serious autoimmune disease affecting blood vessels. The retraction, published ahead of print, follows identification of significant data integrity concerns in the landmark study led by David Jayne at Cambridge University.
Key takeaways
- The New England Journal of Medicine retracted the 2021 Jayne et al. avacopan trial (originally published in volume 384, pages 599-609) due to data integrity violations
- The trial had been widely cited as evidence supporting avacopan’s efficacy in ANCA-associated vasculitis, a rare autoimmune condition affecting small and medium blood vessels
- Data integrity concerns identified during post-publication review have triggered this unprecedented action by one of medicine’s most influential journals
- The retraction raises questions about trial oversight mechanisms and the robustness of peer review processes in high-impact journals
- Healthcare providers treating AAV should review current clinical evidence independently and consult updated treatment guidelines
How a landmark trial unravelled
The original 2021 study, led by Prof. David Jayne, Professor of Vasculitis at the University of Cambridge, examined avacopan, a complement C5a receptor antagonist, in patients with ANCA-associated vasculitis. The trial’s findings had substantial clinical impact: it demonstrated efficacy in reducing disease activity and steroid dependence, leading to regulatory approval and widespread adoption in clinical practice across Europe and North America. The work was positioned as a major advance for a patient population with limited treatment options.
However, subsequent examination of the trial dataset—conducted as part of NEJM’s ongoing quality assurance processes—identified problems with data integrity. The journal’s editors determined these concerns were significant enough to warrant retraction, a rare action reserved for studies where the credibility of findings cannot be maintained.
High-Impact Journal Retractions by Category, 2018–2024
Number of retractions in leading peer-reviewed journals, showing rarity of data integrity retractions in top-tier publications
Source: Retraction Watch Database analysis, 2024 | Georgian Medical Journal News
Clinical implications for ANCA-associated vasculitis treatment
ANCA-associated vasculitis is a rare systemic autoimmune disease affecting small and medium-sized blood vessels, causing inflammation in the lungs, kidneys, skin, and nerves. The condition carries significant morbidity and mortality: according to epidemiological literature, untreated AAV can lead to rapid kidney failure, pulmonary haemorrhage, and multi-organ involvement. Standard care has historically relied on high-dose corticosteroids combined with immunosuppressive agents such as cyclophosphamide or rituximab, both of which carry substantial adverse effect burdens.
The now-retracted trial had suggested avacopan could reduce reliance on long-term corticosteroid therapy—a particularly valuable finding given glucocorticoid-associated toxicity in chronic treatment. However, the retraction casts uncertainty on this evidence base. Clinicians treating AAV patients currently taking avacopan should: (1) review the current clinical updates on AAV management, (2) consult existing randomised evidence from other sources, and (3) engage in shared decision-making with patients about continuation, modification, or alternative therapies.
The retraction of the Jayne et al. trial underscores the critical importance of data integrity in clinical research—particularly in rare disease populations where individual trials can substantially shape treatment paradigms.
— Editorial guidance, New England Journal of Medicine (2026)
Strengthening research oversight and trust
This retraction adds to a documented trend of increasing scrutiny on clinical trial data quality. According to analysis by researchers examining trial oversight mechanisms, data integrity issues identified post-publication have become more common as journals invest in statistical auditing and source-data verification. The New England Journal of Medicine’s approach—proactive identification and transparent retraction—represents a best-practice model, though it raises systemic questions about how such issues reach publication in the first place.
For clinical researchers and trial sponsors, this case reinforces several principles: independent data monitoring committees must have genuine authority to inspect raw source data, electronic data capture systems should incorporate automated validity checks, and institutions must foster a culture where data integrity concerns can be raised without institutional or financial pressure.
In Georgia, where clinical research capacity has grown significantly, health authorities and research ethics committees should ensure that locally-conducted trials adhere to international standards for data management and oversight, with particular attention to rare disease registries that may involve smaller sample sizes and heightened publication pressure.
Implications for regulatory approval and post-market surveillance
The retraction raises important questions about the regulatory lifecycle of pharmaceuticals approved partly on the basis of the now-withdrawn evidence. Avacopan (Fabhalta) received European Medicines Agency (EMA) approval in 2021 and US Food and Drug Administration (FDA) approval in 2023, both substantiated in part by the Jayne et al. trial. EMA and FDA pharmacovigilance systems will assess whether any regulatory action is warranted. Typically, single-trial retractions do not automatically trigger approval withdrawals if additional supportive evidence exists, but regulators must ensure transparency with healthcare professionals about the evidentiary base.
This case underscores the importance of post-market surveillance and adverse event monitoring as a complement to pre-approval trial evidence. Real-world effectiveness and safety data accumulating in clinical registries can provide crucial independent validation—or refutation—of trial findings.
What this means
Frequently asked questions
Does the retraction mean avacopan is unsafe or ineffective?
Not necessarily. The retraction reflects data integrity problems in this particular trial, not direct evidence that the drug is harmful. However, it removes one key source of evidence supporting its efficacy in ANCA-associated vasculitis. Other clinical evidence, registry data, and real-world experience will help determine avacopan’s actual clinical value. Regulatory agencies and clinicians will assess what action, if any, is warranted based on the full evidence picture.
Should patients stop taking avacopan immediately?
No. A journal retraction, while serious, does not automatically translate to a clinical practice change or drug recall. Patients should discuss any concerns with their treating physician, who can evaluate whether continued use remains appropriate based on disease control, side effects, and availability of alternatives. Stopping an immunosuppressive therapy abruptly without medical guidance can cause disease flare.
How do data integrity problems in clinical trials occur, and can they be prevented?
Data integrity issues can arise from honest mistakes in data entry, inadequate quality control processes, or, in serious cases, research misconduct. Prevention requires robust systems: electronic data capture with automated validity checks, independent data monitoring committees with access to source data, regular audit trails, and institutional research integrity training. International Good Clinical Practice (GCP) standards provide frameworks, but their implementation varies. Journals and funders must invest in post-publication verification.
As the medical community absorbs this retraction, the broader lesson is that robust peer review, rigorous data oversight, and transparent post-publication scrutiny are essential safeguards—particularly in rare disease populations where individual trials carry outsized clinical influence. The GMJ News coverage of emerging evidence will continue to highlight how medical knowledge is validated, corrected, and refined over time.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
